Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.54 |
| ▸ | KIT | P10721 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371670 | 0.87 | MET (0.60) | METPDGFRAKITKDRAXL | |
| SCHEMBL379021 | 0.84 | MET (0.77) | METPDGFRAKITKDRAXL | |
| SCHEMBL371747 | 0.82 | MET (0.55) | METPDGFRAKITKDRAXL | |
| SCHEMBL19711758 | 0.81 | MET (0.62) | METPDGFRAKITKDRAXL | |
| SCHEMBL10452730 | 0.81 | PDGFRA (0.56) | METPDGFRAKITKDRSRC | |
| SCHEMBL371958 | 0.80 | PDGFRA (0.61) | METPDGFRAKITKDRAXL | |
| SCHEMBL5001922 | 0.80 | AXL (0.53) | METPDGFRAKITKDRAXL | |
| SCHEMBL371594 | 0.79 | MET (0.61) | METPDGFRAKITKDRAXL | |
| SCHEMBL2363331 | 0.78 | AXL (0.60) | METPDGFRAKITKDRAXL | |
| SCHEMBL377281 | 0.78 | MET (0.53) | METPDGFRAKITKDRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885PDGFRA 182/4885KIT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.